Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK3 | Q9NZJ5 | 20/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | EIF2AK2 | P19525 | 3/20 | 0.49 |
| ▸ | EIF2AK1 | Q9BQI3 | 3/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.49 |
| ▸ | EIF2AK4 | Q9P2K8 | 2/20 | 0.49 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29911812 | 1.00 | EIF2AK3 (0.49) | EIF2AK3CYP3A4EIF2AK2EIF2AK1CYP2C9 | |
| Hydrochloric Acid SCHEMBL23042914 | 0.99 | EIF2AK3 (0.48) | EIF2AK3CYP3A4EIF2AK2EIF2AK1CYP2C9 | |
| Hydrochloric Acid SCHEMBL868686 | 0.99 | EIF2AK3 (0.48) | EIF2AK3CYP3A4EIF2AK2EIF2AK1CYP2C9 | |
| SCHEMBL27889174 | 0.87 | EIF2AK3 (0.40) | EIF2AK3CYP3A4EIF2AK2EIF2AK1CYP2C9 | |
| SCHEMBL30120830 | 0.86 | KDR (0.49) | EIF2AK3 | |
| SCHEMBL24650622 | 0.86 | KDR (0.49) | EIF2AK3 | |
| Hydrochloric Acid SCHEMBL868325 | 0.86 | EIF2AK3 (0.39) | EIF2AK3CYP3A4EIF2AK2EIF2AK1CYP2C9 | |
| SCHEMBL23059970 | 0.84 | EIF2AK3 (0.37) | EIF2AK3CYP3A4EIF2AK2EIF2AK1CYP2C9 | |
| SCHEMBL24650662 | 0.84 | SRC (0.48) | EIF2AK3CYP3A4EIF2AK2EIF2AK1CYP2C9 | |
| SCHEMBL24651180 | 0.84 | AXL (0.43) | EIF2AK3CYP3A4EIF2AK2EIF2AK1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220348584-A1 | PERK INHIBITING INDOLINYL COMPOUNDS | HIBERCELL, INC. | 2022-11-03 | — | — | US | disclosed |
| US-20220348584-A1 | PERK INHIBITING INDOLINYL COMPOUNDS | HIBERCELL, INC. | 2022-11-03 | — | — | US | disclosed |
| WO-2021041976-A1 | PERK INHIBITING INDOLINYL COMPOUNDS | HIBERCELL, INC. (US) | 2021-03-04 | — | — | WO | disclosed |
| WO-2021041976-A1 | PERK INHIBITING INDOLINYL COMPOUNDS | HIBERCELL, INC. (US) | 2021-03-04 | — | — | WO | disclosed |
| EP-2549868-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-01-07 | — | — | EP | disclosed |
| CN-102917588-B | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2014-10-08 | — | — | CN | disclosed |
| US-8598156-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-12-03 | — | — | US | disclosed |
| CN-102917588-A | Chemical compounds | GLAXOSMITHKLINE LLC | 2013-02-06 | — | — | CN | disclosed |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2013-01-17 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018038-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | EIF2AK3 16/4885CYP3A4 1750/4885EIF2AK2 174/4885 |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | EIF2AK3 16/4885CYP3A4 1750/4885EIF2AK2 174/4885 |
| US-20220348584-A1 | PERK INHIBITING INDOLINYL COMPOUNDS | ATF4, MAP3K10, EEF2K | EIF2AK3 85/4885CYP3A4 3828/4885EIF2AK2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.